One Degree Advisors Inc Invests $244,000 in Johnson & Johnson (NYSE:JNJ)

One Degree Advisors Inc acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,513 shares of the company’s stock, valued at approximately $244,000.

A number of other institutional investors have also added to or reduced their stakes in JNJ. McClarren Financial Advisors Inc. raised its position in shares of Johnson & Johnson by 12.6% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 1,152 shares of the company’s stock valued at $187,000 after buying an additional 129 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Johnson & Johnson by 0.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 451,598 shares of the company’s stock valued at $73,186,000 after purchasing an additional 2,437 shares in the last quarter. Vest Financial LLC lifted its stake in Johnson & Johnson by 5.4% during the third quarter. Vest Financial LLC now owns 332,489 shares of the company’s stock worth $53,883,000 after purchasing an additional 16,996 shares during the last quarter. West Branch Capital LLC increased its position in shares of Johnson & Johnson by 2.8% during the 3rd quarter. West Branch Capital LLC now owns 24,890 shares of the company’s stock valued at $4,034,000 after purchasing an additional 688 shares during the last quarter. Finally, Atlas Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $660,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Royal Bank of Canada increased their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. TD Cowen reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Citigroup increased their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Up 0.4 %

NYSE:JNJ opened at $165.12 on Monday. The firm has a market capitalization of $397.39 billion, a P/E ratio of 10.29, a PEG ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company’s 50-day simple moving average is $162.98 and its 200 day simple moving average is $154.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.66 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.